Merck is set to create a separate cancer business to offset the loss of patent for its top-selling drug Keytruda, according to a report by the Wall Street Journal. This move comes as the company prepares for the loss of certain patent protections for Keytruda in 2028, which could expose it to intense competition from lower-cost copycats.
Merck is splitting its human-health business into two divisions to offset pressures related to the loss of patent for its top-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including Keytruda, while the other will sell its non-cancer products.
Keytruda, approved for several forms of cancers, recorded sales of more than $30 billion in 2025. The drug is set to lose certain patent protections in 2028, exposing it to intense competition from lower-cost copycats. Merck has been pursuing several deals over the past year to fill up its pipeline and create new blockbuster growth drivers.
The company’s decision to create a separate cancer business is seen as a strategic move to mitigate the impact of the patent loss on its revenue. By separating its cancer drugs from its non-cancer products, Merck aims to focus on the development and commercialization of its cancer treatments, including Keytruda.
According to the report by the Wall Street Journal, Merck’s move is also seen as a way to attract investors who are interested in the company’s cancer business. The separation of the two divisions is expected to provide more clarity on the company’s financial performance and growth prospects.
The news of Merck’s plan to create a separate cancer business has been well-received by investors, with the company’s shares rising 1.4% in premarket trading. The move is seen as a positive step towards securing the company’s long-term growth and profitability.
As reported by Reuters, Merck did not immediately respond to a request for comment on the matter. However, the company’s decision to create a separate cancer business is seen as a strategic move to stay ahead in the competitive pharmaceutical industry.
For investors, Merck’s decision to create a separate cancer business provides a unique opportunity to invest in a company that is committed to the development and commercialization of innovative cancer treatments. With the separation of the two divisions, investors will have more clarity on the company’s financial performance and growth prospects, making it easier to make informed investment decisions.
In conclusion, Merck’s plan to create a separate cancer business is a strategic move that aims to mitigate the impact of the patent loss on its revenue and secure the company’s long-term growth and profitability. As the pharmaceutical industry continues to evolve, Merck’s decision to focus on its cancer business is seen as a positive step towards staying ahead in the competitive market.
If you’re looking for the fastest and most insightful analysis of breaking financial news, look no further than onlytrustedinfo.com. Our team of expert analysts provides timely and definitive guides to help investors make informed decisions. Stay ahead of the curve and read more articles on our site to get the latest news and analysis on the financial market.
